403 related articles for article (PubMed ID: 33268960)
1. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
Muzica CM; Stanciu C; Huiban L; Singeap AM; Sfarti C; Zenovia S; Cojocariu C; Trifan A
World J Gastroenterol; 2020 Nov; 26(43):6770-6781. PubMed ID: 33268960
[TBL] [Abstract][Full Text] [Related]
2. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
3. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
[TBL] [Abstract][Full Text] [Related]
4. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Kawagishi N; Suda G; Yamamoto Y; Baba M; Furuya K; Maehara O; Ohnishi S; Yoshida S; Fu Q; Yang Z; Hosoda S; Tokuchi Y; Kitagataya T; Ohara M; Suzuki K; Nakai M; Sho T; Natsuizaka M; Ogawa K; Sakamoto N
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680221
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
6. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
8. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
10. Chronic Hepatitis C: Advances in Therapy and the Remaining Challenges.
Alqahtani SA; Sulkowski MS
Med Clin North Am; 2023 May; 107(3):423-433. PubMed ID: 37001945
[TBL] [Abstract][Full Text] [Related]
11. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
12. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
13. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
[TBL] [Abstract][Full Text] [Related]
14. DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA.
Gogichaishvili L; Lobjanidze G; Tsertsvadze T; Chkhartishvili N; Jangavadze M
Georgian Med News; 2020 Sep; (306):76-81. PubMed ID: 33130651
[TBL] [Abstract][Full Text] [Related]
15. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C.
Ahn YH; Lee H; Kim DY; Lee HW; Yu SJ; Cho YY; Jang JW; Jang BK; Kim CW; Kim HY; Park H; Cho HJ; Park B; Kim SS; Cheong JY
Gut Liver; 2021 May; 15(3):410-419. PubMed ID: 32893194
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.
Villani R; Vendemiale G; Serviddio G
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583555
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence.
Celsa C; Stornello C; Giuffrida P; Giacchetto CM; Grova M; Rancatore G; Pitrone C; Di Marco V; Cammà C; Cabibbo G
Ann Hepatol; 2022 Jan; 27 Suppl 1():100568. PubMed ID: 34699987
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
20. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]